Anti-CD20 monoclonal antibodies: historical and future perspectives

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as...

Full description

Saved in:
Bibliographic Details
Main Authors: Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W.M., Glennie, Martin J., Cragg, Mark S.
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2010
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805725/
https://ncbi.nlm.nih.gov/pubmed/19773256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2008.001628
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items